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Abstract
Background: People with serious mental illness (SMI) have significant unmet mental health needs. Development and testing
of digital interventions that can alleviate the suffering of people with SMI is a public health priority.
Objective: The aim of this study is to conduct a fully remote randomized waitlist-controlled trial of CORE, a smartphone
intervention that comprises daily exercises designed to promote reassessment of dysfunctional beliefs in multiple domains.
Methods: Individuals were recruited via the web using Google and Facebook advertisements. Enrolled participants were
randomized into either active intervention or waitlist control groups. Participants completed the Beck Depression Inventory-Second
Edition (BDI-II), Generalized Anxiety Disorder-7 (GAD-7), Hamilton Program for Schizophrenia Voices, Green Paranoid Thought
Scale, Recovery Assessment Scale (RAS), Rosenberg Self-Esteem Scale (RSES), Friendship Scale, and Sheehan Disability Scale
(SDS) at baseline (T1), 30-day (T2), and 60-day (T3) assessment points. Participants in the active group used CORE from T1 to
T2, and participants in the waitlist group used CORE from T2 to T3. Both groups completed usability and accessibility measures
after they concluded their intervention periods.
Results: Overall, 315 individuals from 45 states participated in this study. The sample comprised individuals with self-reported
bipolar disorder (111/315, 35.2%), major depressive disorder (136/315, 43.2%), and schizophrenia or schizoaffective disorder
(68/315, 21.6%) who displayed moderate to severe symptoms and disability levels at baseline. Participants rated CORE as highly
usable and acceptable. Intent-to-treat analyses showed significant treatment×time interactions for the BDI-II (F1,313=13.38;
P<.001), GAD-7 (F1,313=5.87; P=.01), RAS (F1,313=23.42; P<.001), RSES (F1,313=19.28; P<.001), and SDS (F1,313=10.73;
P=.001). Large effects were observed for the BDI-II (d=0.58), RAS (d=0.61), and RSES (d=0.64); a moderate effect size was
observed for the SDS (d=0.44), and a small effect size was observed for the GAD-7 (d=0.20). Similar changes in outcome
measures were later observed in the waitlist control group participants following crossover after they received CORE (T2 to T3).
Approximately 41.5% (64/154) of participants in the active group and 60.2% (97/161) of participants in the waitlist group were
retained at T2, and 33.1% (51/154) of participants in the active group and 40.3% (65/161) of participants in the waitlist group
were retained at T3.
Conclusions: We successfully recruited, screened, randomized, treated, and assessed a geographically dispersed sample of
participants with SMI entirely via the web, demonstrating that fully remote clinical trials are feasible in this population; however,
study retention remains challenging. CORE showed promise as a usable, acceptable, and effective tool for reducing the severity
of psychiatric symptoms and disability while improving recovery and self-esteem. Rapid adoption and real-world dissemination
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of evidence-based mobile health interventions such as CORE are needed if we are to shorten the science-to-service gap and
address the significant unmet mental health needs of people with SMI during the COVID-19 pandemic and beyond.
Trial Registration: ClinicalTrials.gov NCT04068467; https://clinicaltrials.gov/ct2/show/NCT04068467
(J Med Internet Res 2021;23(11):e29201) doi: 10.2196/29201
KEYWORDS
mobile health; schizophrenia; bipolar disorder; depression; mobile phone

Introduction
Background
People with serious mental illnesses (SMIs), including
schizophrenia-spectrum disorders, bipolar disorder, and severe
and persistent depression, experience significant psychiatric
symptoms such as hallucinations, delusions, and severe mood
episodes. SMI is often accompanied by functional and
psychosocial impairments, housing and employment challenges,
and poverty [1-3]. Treatment of people with SMI typically takes
place in publicly funded clinics and community mental health
centers that are chronically underresourced, understaffed, and
overextended [4,5]. These public sector agencies are rarely able
to meet the demand for services [6]. Barriers in the capacity to
provide high-quality care on the provider’s side may be
compounded by hesitancy around treatment seeking on the
patient’s side [7]. People with SMI are often exposed to
pervasive societal stigma about their conditions and therefore
can be reluctant to openly seek services at a clinic if it risks
them being labeled mentally ill [8,9]. The consequence of these
intersecting challenges is a vicious cycle in which those who
are most impaired receive the least amount of support, thus
deteriorating even more over time.
People with SMI are not dramatically different from the general
population in their use of mobile technologies [10,11]. Owing
to subsidy programs that offer people with disabilities access
to mobile phones and data plans (eg, Federal Communications
Commission Lifeline Program) and the dropping prices of
mobile phones worldwide, people with SMI now have
unprecedented opportunities to access information, stay
connected to others, and potentially receive services remotely
via personal mobile devices [12]. Survey studies conducted in
recent years have shown that approximately two-thirds of people
with SMI in the United States already own smartphones and
that most are interested in leveraging them to support their health
care [13-16]. Academic research groups and commercial
companies are responding to the opportunity and have begun
to develop and test a range of smartphone-supported digital
health technologies for people with SMI, including illness
self-management apps, virtual peer support platforms, and
sensor-enabled remote patient monitoring systems [17-19].
Conducting the research necessary to demonstrate the safety
and clinical utility of novel smartphone interventions for people
with SMI is challenging and costly. Recruitment of participants
for clinical trials is the most salient cause of study delays and
a major obstacle in expeditiously moving novel and potentially
helpful interventions to real-world practice [20]. Traditional
participant recruitment strategies are dependent on collaborative
https://www.jmir.org/2021/11/e29201
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partnerships with study sites and clinician referrals [21]. This
creates potential biases in clinical trial samples, as the enrolled
individuals already need to be known by health care providers
and be actively receiving care to be offered the opportunity to
engage in research. Therefore, the participant samples used in
standard clinical trials may be particularly unrepresentative of
hard-to-reach populations, such as people with SMI, who are
known to disengage from clinic-based services for extended
periods [22,23].
To overcome these obstacles, a growing number of studies have
used web-based participant recruitment strategies, including
social media advertisements, virtual outreach through web-based
interest groups, search engine advertisements, and various other
website campaigns. Across clinical populations, these efforts
have yielded impressive results in terms of cost-effectiveness,
time efficiency, and reach [24]. In clinical trials where the
experimental intervention is digital and behavioral in nature (ie,
does not require direct contact between a patient and a provider)
and the comparator condition does not require in-person contact
with the research team (eg, no intervention control, waitlist
control, or digital attention–control alternative), recruitment,
treatment, and assessment of outcomes can all be conducted
fully remotely and potentially on a single device [25-30]. To
our knowledge, fully remote randomized controlled trials have
not been conducted with people with SMI [24].

Objective
Here, we report the first fully remote randomized controlled
clinical trial of a mobile health (mHealth) intervention for people
with SMI. The first objective of this study is to evaluate whether
individuals with SMI can be successfully recruited, assessed,
and engaged in a digital intervention in a fully remote clinical
trial. The second objective of the study is to evaluate the clinical
effectiveness of the CORE intervention, a smartphone app
designed to challenge dysfunctional thoughts that underlie
common symptoms of SMI, self-stigmatizing attitudes, and
maladaptive beliefs that impede treatment seeking and recovery.

Methods
Study Design
This study involved a fully remote randomized controlled
crossover waitlist trial design. All participants were given the
opportunity to receive the study intervention. Following
enrollment, participants were randomized to either receiving
the CORE intervention (indicated as 1) or being in the waitlist
control group (indicated as 0) in blocks of 4. The group
allocation for each block was selected randomly from a list of
6 possible sequences (ie, 1100, 1010, 1001, 0110, 0101, and
J Med Internet Res 2021 | vol. 23 | iss. 11 | e29201 | p. 2
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0011). In the active intervention group, participants completed
the baseline assessment and were then immediately given access
to the CORE app for 30 days of use. After a month, they
concluded the intervention, uninstalled the app, and completed
a second assessment. After an additional month (at 60 days),
they completed a third assessment to measure the stability of
symptom change post intervention. In the control arm,
participants waited 30 days to receive the CORE app. After a
month, they completed a second assessment and were provided
access to the CORE app. After an additional month (at 60 days),
they completed a third assessment to measure within-subject
changes.

Procedures
All study procedures were reviewed and approved by the
institutional review board of the University of Washington (ID
number 00006898). We put a detailed and institutional review
board–approved plan in place to respond to cases of increased
risk. Web-based recruitment was conducted through
advertisements on Google and Facebook. Google advertisements
are presented depending on the user’s search terms. For this
study, we selected a range of terms associated with severe
mental illness (eg, schizophrenia, bipolar, seeing things, and
am I crazy) and related keywords generated by the Google broad
match algorithm. Facebook advertisements use a similar
methodology to target individual interests. For this study, we
targeted interests such as mental health and schizophrenia.
Individuals who clicked on the advertisements were directed to
the study website. The study website provided written and video
descriptions of the project, a downloadable version of the study
consent form, and an option to complete a screening
questionnaire via a see if I am eligible button. If eligible,
participants were again presented with the consent form and
were required to answer questions demonstrating their
understanding of the study details. If they answered these
questions correctly within 3 attempts, they could proceed to the
baseline assessments. Participants were excluded if they were
unable to complete this step successfully, as they were deemed
unable to provide informed consent. Participants completed a
battery of self-report questionnaires on the web at baseline. If
participants’ responses to questionnaires indicated the presence
of suicidal ideation, they were immediately provided with
resources for emergency support. Upon completion of baseline
questionnaires, participants were randomized to either an active
intervention or waitlist control group. Those randomized to the
active intervention arm were given instructions on how to
download and install the CORE mobile app.
At the start of the study period, staff contacted participants via
email or SMS text messaging to welcome them to the study and
remind them to complete the follow-up assessments at 30 and
60 days. After this welcome message, participants interacted
with the study team only if they reached out to the study staff
for technical support. When participants were due for an
assessment, they were sent an automated SMS text message to
alert them to complete the battery through a weblink.
Participants were incentivized by being entered into lotteries to
win US $500 and US $1000 after completing the 30- and 60-day
assessments, respectively.
https://www.jmir.org/2021/11/e29201
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A member (JT) of our research team who was blinded to
participant allocation completed all study analyses, and these
analyses were determined beforehand. All outcome measures
were preselected by the study team and examined in this study.
The sample size was calculated to fit analytic requirements, and
study recruitment was discontinued once the required sample
size was met.

Participants
Participants were eligible if they could speak English; were
aged >18 years; lived in the United States; self-reported a
diagnosis of schizophrenia or schizoaffective disorder, bipolar
disorder, or major depressive disorder; and owned a smartphone
with a data plan. They were excluded if they had previously
participated in the study or were unavailable for 60 days of
participation.

Assessments
At all assessments, we administered measures of depression
(Beck Depression Inventory–II [BDI-II] [31]), anxiety
(Generalized Anxiety Disorder–7 [GAD-7] [32]), auditory
hallucinations (Hamilton Program for Schizophrenia Voices
Questionnaire [HPSVQ] [33]), paranoid thinking (Green
Paranoid Thoughts Scale [GPTS] [34]), recovery (Recovery
Assessment Scale [RAS] [35,36]), self-esteem (Rosenberg
Self-Esteem Scale [RSES] [37]), social isolation (The Friendship
Scale [38]), and functional disability (Sheehan Disability Scale
[SDS] [39]). At baseline, we collected information from
participants regarding demographics and technology use. After
the intervention period, participants also completed a 26-item
self-report usability and acceptability measure comprising
adapted items from the System Usability Scale [40], Post Study
System Usability Questionnaire [40], Technology Assessment
Model Measurement Scales [41], and Usefulness, Satisfaction,
and Ease questionnaire [42]. Participants were asked to rate
their agreement with a series of statements about the
intervention. A similar measure was used in previous studies
conducted by our group [43].

Intervention Description
The CORE intervention is a smartphone app that uses the
GGtude platform, a system designed to increase the cognitive
flexibility of individuals struggling with a range of mental health
problems through brief daily training [44-47]. CORE was
specifically designed to help counteract dysfunctional thoughts
in multiple domains that are relevant to the subjective experience
of having SMI. The intervention comprises daily brief game-like
exercises designed to produce changes in the relative activation
of adaptive and maladaptive beliefs about the self, others, and
the world such that adaptive beliefs would be more easily
retrieved than maladaptive ones.
CORE users were trained to respond to multiple statements in
a sequence of modules that progress through the following
domains: self-talk, belief in change, self-stigma, self-care,
self-worth, illness and identity, personal strength, social
avoidance, feelings versus facts, catastrophization, thoughts of
reference, paranoid ideation (ie, people are against me),
treatment seeking, and recovery. The modules begin with brief
psychoeducation about the target domain and how maladaptive
J Med Internet Res 2021 | vol. 23 | iss. 11 | e29201 | p. 3
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beliefs can hamper recovery. Thoughts appear as statements on
the smartphone screen, and users are required to either endorse
(ie, drag the statement down toward them on the touchscreen)
or discard them (ie, push the statement upwards away from
them). Users learn to embrace self-statements reflecting more
nuanced adaptive thoughts (eg, belief in change, importance of
self-care, alternative explanations to threat perceptions, and
value of treatment seeking). The module content was organized

Ben-Zeev et al
into 53 levels, and participants were recommended to not
complete more than 3 levels a day for a period of 30 days. Push
notifications reminded users to complete their daily training.
After each level, participants had the option of adding to their
personal toolbox 1 of 3 positive statements that they most related
to. Participants could access their toolbox at any time. Figure
1 depicts screenshots of the targeted beliefs menu, an example
of a maladaptive statement, and a psychoeducational element.

Figure 1. Screenshots of the (a) targeted beliefs menu, (b) an example of a maladaptive statement, and (c) a psychoeducational element.

Data Analysis
Means, SDs, and frequencies were reported using descriptive
statistics for all participant demographics, symptom measures,
and acceptability and usability scale items. A series of t tests
and chi-square tests were used to test for group differences in
demographic variables and symptom measures at baseline (T1)
before examining intervention effects at 30 days (T2) and 60
days (T3). Pre- and postscores for both groups were explored
using a series of repeated-measures analysis of variance
(ANOVA). The intervention effect between groups at T2 was
initially tested using a 2×2 mixed-design repeated-measures
ANOVA, controlling for participant diagnosis and baseline
assessment scores. A 1×3 repeated measures ANOVA tested
the performance of the active group across T1, T2, and T3, with
post hoc Bonferroni pairwise comparisons used to explore
outcomes when significant differences occurred. Finally, a series
of 1×3 repeated measures ANOVAs tested the intervention
effect after crossover (T2 and T3) for the waitlist control group
participants to see if intervention effects were replicated. A
series of equivalence tests were conducted using independent
sample 2-tailed t tests to determine whether the magnitude of
intervention effects differed for the active group participants
between T1 and T2 as compared with the intervention effect
for waitlist control participants between T2 and T3. Spaghetti
plots were provided to visualize changes over time across
symptom measures in both groups. To minimize bias during
analysis, we used an intent-to-treat approach and implemented
a multiple imputation strategy to replace missing values [48].
Multiple imputation is considered the most appropriate method
https://www.jmir.org/2021/11/e29201
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of handling missing data for a study of this size, has been used
successfully in repeated measure designs, and has been shown
to have utility with levels of missing data greater than that
observed in this study [49,50]. Sensitivity analyses using
pattern-mixture models were used to establish data that were
missing at random before imputation [51]. Our imputation model
was specified using data from participants in each condition
and included participant demographic variables (ie, diagnosis,
gender, age, and race) and all baseline assessment scores.

Results
Recruitment and Enrollment
Web-based recruitment advertisements were placed between
January 2020 and September 2020, using a total budget of US
$2984.26. We recruited a total of 1123 people from these
advertisements; of these 1123 people, 315 (28.04%) were
randomized for the trial, and 808 (71.95%) were excluded. Of
the 315 participants, 154 (48.9%) dropped out of the study
before T2 and 45 (14.3%) dropped out between T2 and T3.
Approximately 41.5% (64/154) of participants in the active
group and 60.2% (97/161) of participants in the waitlist group
were retained at T2, and 33.1% (51/154) of participants in the
active group and 40.3% (65/161) of individuals in the waitlist
group were retained at T3. Those who dropped out of the study
were not found to differ significantly from those who were
retained in terms of demographic characteristics or baseline
scores on outcome measures (Figure 2). Most participants were
recruited from Google advertisements (226/315, 71.7%).
Overall, Google advertisements were viewed 557,700 times
J Med Internet Res 2021 | vol. 23 | iss. 11 | e29201 | p. 4
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and were ultimately clicked on 5100 times. The states with the
most clicks on the Google advertisement were California
(540/5100, 10.59%), Texas (393/5100, 7.71%), Florida
(295/5100, 5.78%), and New York (294/5100, 5.77%). The
most successful Google advertisement keywords for increasing
engagement from potential participants were mental health,
mental illness, depression, illuminati, and bipolar. Most
individuals (4734/5100, 92.82%) clicked on the advertisement
through mobile phones, whereas few used desktop computers

Ben-Zeev et al
(256/5100, 5.02%) or tablets (110/5100, 2.16%). Participants
that enrolled in the study were recruited from 45 states (Figure
3), with the most participants coming from California (24/315,
7.6%), Texas (21/315, 6.7%), Florida (17/315, 5.4%), New
York (16/315, 5.1%), Pennsylvania (16/315, 5.1%), and
Washington (16/315, 5.1%). We successfully enrolled
participants from 80% (12/15) of the most rural states in the
country.

Figure 2. CONSORT (Consolidated Standards of Reporting Trials) diagram.

Figure 3. Map of participants enrolled based on location.

Demographics
Full demographics of the study participants are reported in Table
1. The final study participants were mostly female (264/315,
83.8%), White (241/315, 76.5%), heterosexual (218/315,
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69.2%), living independently (150/315, 47.6%) or with family
(136/315, 43.2%), unemployed (210/315, 66.7%), and aged
between 18-78 years. No demographic differences were
observed following randomization between the 2 study groups.
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Table 1. Participant demographics and clinical history at baseline (N=315).
Characteristics

Waitlist (n=161)

Active (n=154)

Age (years), mean (SD)

36.85 (10.91)

38.98 (12.30)

Female

132 (82)

132 (85.7)

Male

19 (11.8)

18 (11.7)

Transgender

6 (3.7)

0

MTFa

2 (1.2)

0

FTMb

4 (2.5)

0 (0)

Nonbinary

4 (2.5)

2 (1.3)

Other

0

2 (1.3)

Bipolar disorder

61 (37.9)

50 (32.5)

Major depressive disorder

67 (41.6)

69 (44.8)

Schizophrenia or schizoaffective disorder

33 (20.5)

35 (22.7)

White

118 (73.3)

123 (79.9)

Black or African American

20 (12.4)

12 (7.8)

Asian

6 (3.7)

4 (2.6)

Alaskan Native or American Indian

1 (0.6)

1 (0.6)

Declined to answer

0

1 (0.6)

More than one race

16 (9.9)

13 (8.4)

Spanish, Hispanic, or Latino

17 (10.6)

13 (8.4)

Not Spanish, Hispanic, or Latino

143 (89.4)

139 (91.4)

Finished eighth grade

3 (1.9)

1 (0.7)

Some high school

10 (6.2)

5 (3.3)

High school diploma

31 (19.3)

22 (14.4)

Some college or technical school

47 (41.6)

62 (40.5)

Associate’s degree

15 (9.3)

21 (13.7)

Bachelor’s degree

26 (16.1)

22 (14.4)

Some graduate school

1 (0.6)

6 (3.9)

Master’s degree

7 (4.3)

13 (8.5)

Doctorate

1 (0.6)

1 (0.7)

Full-time

23 (14.3)

29 (19)

Part-time

27 (16.8)

17 (11.1)

Unemployed

105 (65.2)

105 (68.6)

Independent

78 (48.4)

72 (47.1)

Living with family

71 (44.1)

65 (42.5)

Homeless

6 (3.7)

10 (6.5)

Gender, n (%)

Diagnosis, n (%)

Race, n (%)

Ethnicity, n (%)

Education, n (%)

Employment status, n (%)

Living situation, n (%)
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Waitlist (n=161)

Active (n=154)

Substance use treatment

0

1 (0.7)

Assisted or supported living

6 (3.7)

5 (3.3)

0

49 (30.4)

44 (28.8)

1-5

69 (42.9)

72 (47.1)

6-10

20 (12.4)

18 (11.8)

11-15

11 (6.8)

5 (3.3)

16-20

3 (1.9)

3 (2)

>20

9 (5.6)

11 (7.2)

0

127 (78.9)

114 (74.5)

1-5

33 (20.5)

37 (24.2)

6-10

1 (0.6)

2 (1.3)

Never

82 (51.9)

75 (49)

A few times a year

24 (15.2)

23 (15)

Once or twice a month

17 (10.8)

15 (9.8)

Once a week

5 (3.2)

9 (5.9)

≥2 times a week

30 (19)

31 (20.3)

Beck Depression Inventory-II, mean (SD)

34.57 (13.34)

33.46 (13.75)

Green Paranoid Thought Scale, mean (SD)

88.24 (35.63)

86.79 (36.01)

Hamilton Program for Schizophrenia Voices, mean (SD)

19.86 (9.03)

18.42 (8.81)

Generalized Anxiety Disorder–7, mean (SD)

13.89 (5.77)

14.42 (5.16)

Sheehan Disability Scale, mean (SD)

24.11 (7.21)

24.11 (7.02)

Lifetime psychiatric hospitalizations, n (%)

Past-year psychiatric hospitalizations, n (%)

Frequency of auditory hallucinations, n (%)

a

MTF: male-to-female.

b

FTM: female-to-male.

Clinical Characteristics
The sample comprised individuals with bipolar disorder
(111/315, 35.2%), major depressive disorder (136/315, 43.2%),
and schizophrenia or schizoaffective disorder (68/315, 21.6%).
Approximately a quarter (75/315, 23.8%) of the participants
reported experiencing auditory hallucinations on a weekly or
more frequent basis at baseline. Approximately 23.2% (73/315)
of participants reported experiencing a psychiatric
hospitalization in the past year, and 25.4% (80/315) of
participants reported having ≥6 psychiatric hospitalizations in
their lifetime. Baseline scores on clinical outcome measures
were in the severe range on both the BDI-II (mean 33.95, SD
13.61) and the GPTS (mean 87.51, SD 35.79) and in the
moderate range on the GAD-7 (mean 14.12, SD 5.48) and
HPSVQ (mean 19.08, SD 8.89). Participants had a moderate
level of disability SDS (mean 24.07, SD 7.12). Significant
correlations existed between scores on the BDI-II and GAD-7
(r=0.69; P<.001), BDI-II and GPTS (r=0.38; P<.001), and
GAD-7 and GPTS (r=0.40; P<.001), indicating a high degree
of comorbidity within the sample. No differences were found
between groups on any clinical characteristics or baseline
https://www.jmir.org/2021/11/e29201
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outcome measures after randomization. Diagnosis was not found
to be a significant predictor of completion at T2 or T3, with the
distribution of completion resembling the distribution of
participants at baseline. At T2, 20.5% (33/161) of completers
had a diagnosis of schizophrenia or schizoaffective disorder,
44.1% (71/161) had a diagnosis of major depressive disorder,
and 35.4% (57/161) had a diagnosis of bipolar disorder. At T3,
23.3% (27/116) of completers had a diagnosis of schizophrenia
or schizoaffective disorder, 46.6% (54/116) had a diagnosis of
major depressive disorder, and 30.2% (35/116) had a diagnosis
of bipolar disorder.

Engagement Metrics
We were able to collect the CORE app use data from 51.4%
(162/315) of participants. Of the 162 participants, 82 (50.6%)
completed all 53 intervention levels, whereas participants, on
average, completed 35 levels. Most participants reported that
they would like to use CORE more often; that if they had access
to CORE, they would use it; that the app was easy to use and
sufficiently interactive; and that they did not need technical
support to use CORE. Participants rated that they were satisfied
with the CORE intervention and that they would recommend
J Med Internet Res 2021 | vol. 23 | iss. 11 | e29201 | p. 7
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it to a friend. The distribution of participants’ responses to all
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usability and acceptability questions is displayed in Table 2.

Table 2. Participant usability and acceptability ratings (N=119).
Item

Disagree, n (%)

Neutral, n (%)

Agree, n (%)

I think that I would like to use CORE often.

8 (6.7)

26 (21.8)

85 (71.4)

I thought CORE was easy to use.

1 (0.8)

5 (4.2)

113 (95.0)

I found that the different parts of CORE work well together.

1 (0.8)

23 (19.3)

95 (79.8)

I would imagine that most people would learn to use CORE very quickly.

0 (0.0)

6 (5.0)

113 (95.0)

I felt very confident using CORE.

1 (0.8)

24 (20.2)

94 (79.0)

Overall, I am satisfied with how easy it is to use CORE.

1 (0.8)

8 (6.7)

110 (92.4)

I was able to use the modules quickly in CORE.

3 (2.5)

8 (6.7)

108 (90.8)

I felt comfortable using CORE.

0 (0.0)

9 (7.6)

110 (92.4)

It was easy to learn to use CORE.

0 (0.0)

7 (5.9)

111 (94.1)

Whenever I made a mistake using CORE, I could recover easily and quickly.

2 (1.7)

17 (14.3)

100 (84.0)

It was easy to find the information I needed.

5 (4.2)

16 (13.6)

97 (82.2)

The information provided for CORE was easy to understand.

2 (1.7)

10 (8.5)

105 (89.7)

How things appeared on the screen was clear.

1 (0.8)

9 (7.6)

108 (91.5)

If I have access to CORE, I will use it.

6 (5.0)

17 (14.3)

96 (80.7)

I am satisfied with CORE.

7 (5.9)

11 (9.2)

101 (84.9)

I would recommend CORE to a friend.

6 (5.0)

23 (19.3)

90 (75.6)

CORE is fun to use.

7 (5.9)

44 (37.0)

68 (57.1)

CORE works the way I want it to work.

10 (8.4)

28 (23.5)

81 (68.1)

I feel I need to have CORE.

20 (16.8)

58 (48.7)

41 (34.5)

CORE helped me manage my symptoms.

12 (10.1)

41 (34.5)

66 (55.5)

CORE was interactive enough.

6 (5.0)

26 (21.8)

87 (73.1)

I found CORE to be very complicated

108 (90.8)

7 (5.9)

4 (3.4)

I think that I would need the support of a technical person to be able to use CORE.

103 (86.6)

7 (5.9)

9 (7.6)

I thought there was too much inconsistency in CORE.

99 (83.2)

13 (10.9)

7 (5.9)

I found CORE very awkward to use.

103 (86.6)

11 (9.2)

5 (4.2)

I needed to learn a lot of things before I could get going with CORE.

105 (88.2)

8 (6.7)

6 (5.0)

Between-Group Differences: Active Group Versus
Waitlist Control Group
Analyses of differences between the active group and the waitlist
control group from T1 to T2 revealed a significant
treatment×time interaction effect for the BDI-II (F1,313=13.38;
P<.001), GAD-7 (F1,313=5.87; P=.02), RAS (F1,313=23.42;
P<.001), RSES (F1,313=19.28; P<.001), and SDS (F1,313=10.73;
P=.001). Large effects were observed at T2 for the BDI-II
(d=0.58), RAS (d=0.61), and RSES (d=0.64). A moderate effect
was observed for the SDS (d=0.44) and a small effect for the
GAD-7 (d=0.20).
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This indicates that participants engaging in the active condition
showed improvements on these outcome measures after 30 days
of using the app compared with participants in the waitlist
control group who did not have access to the app over the same
period (Figure 4). A significant main effect of time was found
for the BDI-II (F1,313=44.33; P<.001), GAD-7 (F1,313=66.77;
P<.001), GPTS (F1,313=39.85; P<.001), RAS (F1,313=46.15;
P<.001), RSES (F1,313=28.89; P<.001), Friendship Scale
(F1,313=21.05; P<.001), and SDS (F1,313=51.644; P<.001). Table
3 displays the means and SDs for all measures at each time
point for the active group participants and the waitlist control
group participants.
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Figure 4. Outcome measures (y-axis) at baseline (T1), 30 days (T2), and 60 days (T3) assessments points (x-axis) for active group and waitlist control
group. BDI-II: Beck Depression Inventory-Second Edition; GAD-7: Generalized Anxiety Disorder-7; GPTS: Green Paranoid Thought Scale; HPSVQ:
Hamilton Program for Schizophrenia Voices; RAS: Recovery Assessment Scale; RSES: Rosenberg Self-esteem Scale; SDS: Sheehan Disability Scale.
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Table 3. Comparison of outcome measures across periods for each group.
Measure

Baseline, mean (SD)

30 days, mean (SD)

60 days, mean (SD)

Active

33.46 (13.75)

26.33 (10.43)a,b

24.94 (8.71)

Waitlist

34.57 (13.34)

32.52 (11.12)

24.93 (10.59)b

Active

14.42 (5.16)

10.93 (4.17)b,c

10.75 (3.69)

Waitlist

13.89 (5.77)

12.23 (5.00)d

9.72 (4.53)b

Beck Depression Inventory–II

Generalized Anxiety Disorder-7

Hamilton Program for Schizophrenia Voices Questionnaire
Active

18.42 (8.81)

16.56 (8.54)

18.08 (6.07)

Waitlist

19.86 (9.03)

17.71 (10.20)

18.00 (11.99)

Active

86.79 (36.01)

76.66 (23.97)b

68.84 (20.41)b

Waitlist

88.24 (35.63)

78.59 (27.54)b

65.84 (24.11)b

Active

70.42 (16.62)

81.02 (11.01)a,b

83.64 (9.44)b

Waitlist

71.61 (17.18)

73.38 (12.44)

80.06 (13.08)b

Active

11.45 (6.39)

14.47 (4.28)a,d

14.89 (4.28)

Waitlist

11.43 (5.83)

11.77 (4.96)

14.21 (5.01)b

Active

10.02 (3.84)

11.63 (3.19)b

12.03 (3.00)

Waitlist

10.19 (3.56)

10.96 (3.39)

12.27 (3.28)b

Active

24.12 (7.03)

19.85 (6.26)b,e

18.35 (6.38)d

Waitlist

24.14 (7.21)

22.70 (5.83)d

18.61 (6.54)b

Green Paranoid Thoughts Scale

Recovery Assessment Scale

Rosenberg Self-Esteem Scale

Friendship scale

Sheehan Disability Scale

a

Significance of between-group change within period (active vs waitlist control) <.001.

b

Significance of within-group change from the previous period <.001.

c

Significance of between-group change within period (active vs waitlist control) <.05.

d

Significance of within-group change from the previous period <.01.

e

Significance of between-group change within period (active vs waitlist control) <.01.

Within-Group Change: Active Intervention Group at
T2 and Maintenance at T3
A series of 1×3 repeated-measures ANOVA was used to
examine intervention effects within the active group between
T1 and T2 and whether these effects were maintained 30 days
after discontinuation of app use (Table 3). Results of the
ANOVAs showed significant within-group differences for the
BDI-II (F2,306=43.59; P<.001), GAD-7 (F2, 306=43.71; P<.001),
GPTS (F2, 306=34.39; P<.001), RAS (F2, 306=65.22; P<.001),
RSES (F2, 306=32.85; P<.001), Friendship Scale (F2, 306=17.94;
P<.001), and SDS (F2, 306=56.21; P<.001). Large effect sizes
were observed between T1 and T2 for the active intervention
group on the BDI-II (d=0.60), GAD-7 (d=0.69), RAS (d=0.70),
https://www.jmir.org/2021/11/e29201
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and SDS (d=0.63). Moderate to small effect sizes occurred
during this period on the RSES (d=0.47), GPTS (d=0.35), and
Friendship Scale (d=0.39). No significant change was found at
any time point for the active group for the HPSVQ (F2,
306=0.704; P=.51). Bonferroni post hoc comparisons revealed
significant improvements in each outcome measure at T2 except
for the HPSVQ. All improvements were maintained between
T2 and T3, with an additional small effect noted on the GPTS
(d=0.33), RAS (d=0.27), and SDS (d=0.24), suggesting a
prolonged intervention effect.
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Within-Group Change: Waitlist Control Group at T2
and Following Crossover at T-3
Results from the active group were replicated following
crossover in the waitlist control group between T2 and T3.
Participants in the waitlist control group were found to have
significant differences on the BDI-II (F2, 322=60.79; P<.001),
GAD-7 (F2, 322=50.41; P<.001), GPTS (F2, 322=55.15; P<.001),
RAS (F2, 322=32.03; P<.001), RSES (F2, 322=34.35; P<.001),
Friendship Scale (F2, 322=26.28; P<.001), and SDS (F2,
322=50.93; P<.001). The lack of change in the HPSVQ scores
after 30 days of CORE use was also replicated (F2, 322=1.14;
P=.34). Post hoc analysis revealed that significant improvements
took place for the waitlist control group between T2 and T3 for
all outcome measures except HPSVQ. Effect size magnitudes
were similar to those seen in the active group during the previous
period, with large to moderate effects on the BDI-II (d=0.73),
GAD-7 (d=0.46), GPTS (d=0.48), RAS (d=0.55), RSES
(d=0.52), Friendship Scale (d=0.43), and SDS (d=0.67).
Improvements in the waitlist control group were also found
between T1 and T2 for GAD-7, GPTS, and SDS. These
improvements as a result of time were sufficient to negate a
between-subject effect for the GPTS but not for the BDI-II or
the GAD-7. The magnitude of change observed after 30 days
of CORE use between groups was equivalent across all outcome
metrics except for the RAS (t105=2.28; P=.03), with the active
group showing a slightly larger improvement than the waitlist
control group.

Discussion
Principal Findings
Recent studies have demonstrated the feasibility of conducting
remote trials of digital health apps for common mental health
problems, including stress, anxiety, and depression [27-29].
This paper reports on the first fully remote randomized
controlled trial of a smartphone intervention involving people
with more severe forms of psychopathology, including
schizophrenia and bipolar disorder. Building on and expanding
web-based enrollment strategies used in previous works [52,53],
we were able to reach, recruit, randomize, treat, and assess a
sociodemographically diverse sample of participants from 45
states, far exceeding the reach of traditional localized study
recruitment approaches and at a fraction of the cost. A key
advantage of remote research strategies leveraging web-based
recruitment advertisements lies in the flexibility they afford the
investigative team to determine the geographical regions and
roll out of study recruitment materials. Similar to what has been
shown with other clinical populations [24], this proved to be a
remarkably efficient methodology of reaching people with SMI
who are more impaired and often considered more complex to
engage in research [54].
This study found that a novel smartphone app, CORE, proved
to be usable, acceptable, and effective in improving recovery
and reducing the severity of psychiatric symptoms among
individuals with SMI. Our findings align with an ample body
of digital mental health research suggesting that mHealth
smartphone apps can be of clinical value to people with SMI
https://www.jmir.org/2021/11/e29201
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[17,55,56]. Integration of technology with human support can
bolster the engagement and clinical potency of technology-based
treatments for SMI [57,58]. The CORE intervention was entirely
self-navigated by users in the study who received minimal or
no remote technical support from our study staff. We are not
advocating for a shift toward fully automated approaches as the
preferred model. However, what this study did demonstrate is
that when technology is designed with the characteristics of the
intended users in mind (ie, in terms of functionality,
accessibility, navigability, and content), deployment of specialty
digital mental health tools that do not involve humans in the
loop of care can also produce significant clinical benefits.
The CORE intervention builds on a digital cognitive training
strategy that has been previously demonstrated to reduce
dysfunctional self-talk and increase resilience in
community-based subclinical groups [44-46]. The app included
modules focused on countering maladaptive beliefs in common
mental health domains (eg, self-esteem, distinguishing thoughts
from feelings, social anxiety, and catastrophizing) as well as
modules specifically designed for people with SMI (eg, stigma
related to mental illness, threat perception and persecutory
ideation, hopelessness, strengths-based recovery, self-care, and
treatment seeking). Thus, it is meant to be used
transdiagnostically [59].
Although this study was a fully remote trial that relied entirely
on participants’ self-reports, we are confident that we were able
to reach our intended target audience; most of our study sample
reported having a psychiatric diagnosis of schizophrenia,
schizoaffective disorder, or bipolar disorder; a history of
multiple psychiatric hospitalizations; and being unemployed.
Approximately one-tenth reported being currently homeless or
residing in an assisted-living facility. Combined with the
sample’s average baseline ratings showing moderate to severe
psychiatric symptom severity and moderate to high levels of
disability, our data suggest that the sample comprised people
with significant functional impairment.
The waitlist-controlled study design enabled the evaluation of
both between-group effects during the intervention period and
within-group changes in both groups over time. The results
demonstrated a link between the timing of participants’ exposure
to the treatment app and when they experienced significant
changes in key clinical and functional measures. A combination
of factors such as simplicity, brevity, daily use, and game-like
interactions may have encouraged the use of the CORE app.
Daily practice comprising identification and categorization of
self-statements, repeated exposure to adaptive self-statements,
and psychoeducation may have facilitated retrieval of adaptive
beliefs over maladaptive ones, thereby reducing the severity of
symptoms [60]
This study has several limitations. The opportunity to participate
was available only to individuals who used the internet (ie, to
receive study recruitment advertisements) and who owned
smartphones (ie, to download the CORE app) and therefore
may not be representative of the full range of people with SMI.
Similar to fully remote digital mental health trials involving
participants with less severe psychopathology [61], our study
sample was overrepresented by female participants (264/315,
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83.8%), and study dropout rates were high, requiring significant
data imputation. All screening and assessment questions relied
on individuals’ self-reports but were not corroborated by a
trained clinician or additional documentation (eg, EHR data).
Replication of our findings in samples that were screened,
diagnosed, and assessed by trained clinical assessors could
bolster confidence in the nature of our results. Using a waitlist
control is often considered a more ethical study design than
offering no treatment at all or sham interventions. However, it
may also have artificially inflated estimates of the intervention
effects; asking participants who are ready for treatment to wait
to receive CORE may have frustrated them, stalled their attempts
to make independent changes, or artificially delayed their
seeking other treatment options. Finally, although our measure
of recovery taps willingness to ask for help [35,36], we did not
formally evaluate changes in treatment-seeking behavior, which
is an area of focus in the CORE training program and the key
variable of interest.

Ben-Zeev et al

Conclusions
Mental health researchers, funders, industry leaders, patients,
and their caregivers have been advocating for the development
and deployment of effective digital health tools to improve the
outcomes of people with psychiatric conditions [62,63]. The
global COVID-19 pandemic has led to major disruptions in the
delivery of standard mental health services and has shed light
on the vulnerabilities intrinsic to complete reliance on
clinic-based treatment models [64,65]. In the context of this
ongoing public health crisis, new scientific evidence showing
that remotely-accessed mHealth technologies such as CORE
can be navigable and beneficial to people with SMI is very
encouraging. Regulatory bodies have taken active steps to
remove barriers to the use of digital health technologies for
psychiatric disorders [66]. Currently, rapid adoption and
real-world dissemination of evidence-based digital health
interventions are needed if we are to shorten the
science-to-service gap and help address the significant unmet
mental health needs of people with SMI during the pandemic
and beyond.
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